Nicholas P. Van Der Meulen

Villigen, AG 5232, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 94 publications

Tolerability of [161Tb]Tb-SibuDAB in comparison to other PSMA-targeting radioligands in the preclinical setting.

Tolerability of [161Tb]Tb-SibuDAB in comparison to other PSMA-targeting radioligands in the preclinical setting.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 07, 2026

Hydroxyquinoline-functionalised aza-crown macrocycles for lanthanide coordination.

Hydroxyquinoline-functionalised aza-crown macrocycles for lanthanide coordination.

Journal: Dalton transactions (Cambridge, England : 2003)

Published: February 04, 2026

Production of the Auger-electron emitter 161Ho for nuclear medicine using proton beams.

Production of the Auger-electron emitter 161Ho for nuclear medicine using proton beams.

Journal: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine

Published: December 09, 2025

Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.

Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: June 17, 2025

Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imaging.

Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imaging.

Journal: EJNMMI physics

Published: April 29, 2025

Corrigendum to "Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy" [Nucl Med Biol (March-April 2025) 108990].

Corrigendum to "Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy" [Nucl Med Biol (March-April 2025) 108990].

Journal: Nuclear medicine and biology

Published: March 18, 2025

Development of lisinopril radioconjugates for nuclear imaging of the angiotensin converting enzyme.

Development of lisinopril radioconjugates for nuclear imaging of the angiotensin converting enzyme.

Journal: European journal of nuclear medicine and molecular imaging

Published: March 14, 2025

Light-Induced Synthesis and Radiotheranostic Treatment of Gastric Cancer with 161Tb-Labeled Monoclonal Antibodies.

Light-Induced Synthesis and Radiotheranostic Treatment of Gastric Cancer with 161Tb-Labeled Monoclonal Antibodies.

Journal: JACS Au

Published: February 25, 2025

Quantitative terbium-161 SPECT/CT imaging: demonstrating the feasibility of image-based dosimetry and highlighting pitfalls.

Quantitative terbium-161 SPECT/CT imaging: demonstrating the feasibility of image-based dosimetry and highlighting pitfalls.

Journal: EJNMMI research

Published: November 20, 2024

Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy.

Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy.

Journal: Nuclear medicine and biology

Published: November 09, 2024

161Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with 177Lu in Preclinical Models of Ovarian Cancer.

161Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with 177Lu in Preclinical Models of Ovarian Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: November 04, 2024

First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study.

First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study.

Journal: European journal of nuclear medicine and molecular imaging

Published: October 16, 2024

Showing 1-12 of 94

Last Updated: 09/26/2026